GRAL
GRAL
NASDAQ · Biotechnology

Grail Inc

$61.57
-12.61 (-17.00%)
As of Aug 6, 9:55 PM ET ·
Day Range $60.76 — $70.46
52W Range $29.95 — $118.84

Performance

1D
1W
1M
3M
6M -38.68%
1Y +86.80%
YTD -30.72%
Open$68.00
Previous Close$74.18
Day High$70.46
Day Low$60.76
52W High$118.84
52W Low$29.95
Volume
Avg Volume496.3K
Market Cap3.05B
P/E Ratio
EPS$-10.37
SectorBiotechnology

Technical Indicators

Full analysis →
SMA 50 $97.75 Below
SMA 200 $64.49 Below
RSI (14) 50.6 Neutral
Trend Golden Cross Bullish

Analyst Ratings

Buy
15 analysts
9 Buy 6 Hold 0 Sell
Price Target -45.4% upside
Current
$61.57
Target
$33.59
$28.45 $33.59 avg $56.21

Key Financials

FY 2026 FY 2025 FY 2024
Revenue 178.32M 128.87M 2.02B
Net Income -494,768,326 -321,812,165 154.03M
Profit Margin -277.5% -263.6% 7.6%
EBITDA -518,904,452 -356,261,638 214.07M
Free Cash Flow 137.52M
Rev Growth +38.4% +38.4% +15.5%
Debt/Equity 0.96

Biotechnology Peers

Symbol Name Price Change P/E Mkt Cap
ABBV Abbvie Inc $245.22 +0.55% 122.9 446.67B
AMGN Amgen Inc $407.95 +0.77% 26.5 206.48B
GILD Gilead Sciences Inc $133.75 +2.21% 17.6 161.72B
VRTX Vertex Pharmaceuticals Inc $484.53 -0.06% 27.8 120.52B
REGN Regeneron Pharmaceuticals $782.10 +1.29% 17.5 77.36B
ALNY Alnylam Pharmaceuticals Inc $217.68 +0.72% 47.7 27.52B

Next Earnings

Aug 18, 2026
TBD
10 days away
EPS Est: $-2.71

Quick Stats

Market Cap3.05B
P/E Ratio
EPS$-10.37
Volume
SectorBiotechnology